Caribou Biosciences: Katy Rezvani, Christopher Sturgeon

Caribou Biosciences has appointed Katy Rezvani and Christopher Sturgeon to its scientific advisory board.

Rezvani serves as the Sally Cooper Murray Chair in Cancer Research, chief of the section for cellular therapy, director of translational research, and director of the GMP Facility at the University of Texas MD Anderson Cancer Center. She also serves as executive director of MD Anderson's Adoptive Cell Therapy Platform. Her laboratory focuses on the role of NK cells in mediating immunity against hematologic and solid tumors in order to understand mechanisms of tumor-induced NK cell dysfunction and to develop strategies to genetically engineer NK cells to enhance their in vivo anti-tumor activity and persistence. 

Sturgeon serves as an associate professor at the Icahn School of Medicine at Mount Sinai. His studies focus on characterizing the signal pathways that control human pluripotent stem cell differentiation towards hematopoietic stem/progenitor cells, and how this impacts NK cell development and function. Prior to joining Mount Sinai, Sturgeon was a member of the Washington University School of Medicine hematology division.